Looking for 1628606-05-2 / Vimseltinib API manufacturers, exporters & distributors?
Vimseltinib manufacturers, exporters & distributors
1
85
PharmaCompass offers a list of Vimseltinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Vimseltinib manufacturer or Vimseltinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Vimseltinib manufacturer or Vimseltinib supplier.
API | Excipient name
Vimseltinib
Synonyms
Dcc-3014, 1628606-05-2, Vimseltinib [inn], Vimseltinib [usan], Px9ftm69bf, Dcc3014
Unique Ingredient Identifier (UNII)
PX9FTM69BF
About Vimseltinib
Vimseltinib is an orally bioavailable inhibitor of the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R; CSF-1R; C-FMS; CD115; M-CSFR), with potential antineoplastic, macrophage checkpoint-inhibitory and immunomodulating activities. Upon administration, vimseltinib targets and binds to CSF1R expressed on monocytes, macrophages, and osteoclasts and inhibits the binding of the CSF1R ligands colony-stimulating factor-1 (CSF-1) and interleukin-34 (IL-34), to CSF1R. This prevents CSF1R activation and CSF1R-mediated signaling in these cells. This blocks the production of inflammatory mediators by macrophages and monocytes and reduces inflammation. By blocking the recruitment to the tumor microenvironment (TME) and activity of CSF1R-dependent tumor-associated macrophages (TAMs), vimseltinib inhibits the immunomodulating activity by macrophages and enhances T-cell infiltration and anti-tumor T-cell immune responses, which inhibits the proliferation of tumor cells. TAMs play key roles in the TME and allow for immune suppression; TAMs promote inflammation, tumor cell proliferation, angiogenesis, invasiveness and survival.